miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Mostrar otras versiones (1)

Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT signaling, could be improved by its combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Callegari, Elisa, Guerriero, Paola, Bassi, Cristian, D’Abundo, Lucilla, Frassoldati, Antonio, Simoni, Edi, Astolfi, Laura, Silini, Enrico Maria, Sabbioni, Silvia, Negrini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395755/
https://www.ncbi.nlm.nih.gov/pubmed/36035756
http://dx.doi.org/10.1016/j.omtn.2022.07.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395755/
https://www.ncbi.nlm.nih.gov/pubmed/36035756
http://dx.doi.org/10.1016/j.omtn.2022.07.015

Ejemplares similares